<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732741</url>
  </required_header>
  <id_info>
    <org_study_id>SS2021</org_study_id>
    <nct_id>NCT04732741</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions</brief_title>
  <official_title>Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Synucleins are a family of small, highly conserved proteins found in vertebrates and are&#xD;
      specially abundant in neurons particularly in presynaptic terminals (Surguchov et al., 2001).&#xD;
      Gamma-synuclein is the third member of the synuclein family, and is predominantly found in&#xD;
      the cytosol of tumor cells and functions both intra- and extra-cellularly. It is involved in&#xD;
      the pathogenesis of different types of cancer and some neurodegenerative diseases (Liu et&#xD;
      al., 2018). Smoking - a major risk factor for oral cancer and its progression - and&#xD;
      nicotine-containing products were found to time-dependently up-regulate the Gamma-synuclein&#xD;
      expression in cancer cells (Hsu et al., 2020a).&#xD;
&#xD;
      Gamma-synuclein is released from tumor cells and was found to be elevated in tumors such as&#xD;
      urinary bladder cancer (Liu et al., 2016), colorectal cancer, gastric adenocarcinomas and&#xD;
      esophageal cancer (Liu et al., 2012). It is present in blood, serum, cerebrospinal fluid and&#xD;
      saliva. The detection of extracellular synucleins in body fluids can reveal the first steps&#xD;
      of the disease thus it can be used as a potential tool for early cancer detection (Surguchov,&#xD;
      2016).&#xD;
&#xD;
      This study aims to identify the diagnostic accuracy of Gamma-synuclein in differentiating&#xD;
      between oral malignant lesions and oral premalignant lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2021</start_date>
  <completion_date type="Anticipated">December 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gamma-synuclein level sensitivity and specificity</measure>
    <time_frame>At same time as biopsy</time_frame>
    <description>Measured using ELISA reader</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Oral Cancer</condition>
  <condition>Oral Lichen Planus</condition>
  <condition>Oral Leukoplakia</condition>
  <condition>Premalignant Lesion</condition>
  <arm_group>
    <arm_group_label>Oral Cancer</arm_group_label>
    <description>patients diagnosed clinically and histopathologically with oral cancer who have yet to receive any treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premalignant lesions</arm_group_label>
    <description>patients diagnosed clinically and histopathologically with oral potentially malignant lesions who have not yet to receive treatment or had a month wash-out period from any previous treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>healthy individuals who will be examined clinically through conventional visual and tactile examination to ensure no oral lesions are present and through thorough medical history</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Salivary Gamma-synuclein</intervention_name>
    <description>Gamma-synuclein salivary levels measured using ELISA assay</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Oral Cancer</arm_group_label>
    <arm_group_label>Premalignant lesions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Incisional biopsy</intervention_name>
    <description>A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.&#xD;
B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region.</description>
    <arm_group_label>Oral Cancer</arm_group_label>
    <arm_group_label>Premalignant lesions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Conventional visual and tactile examination</intervention_name>
    <description>Conventional visual and tactile examination using light and mirror</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Oral Cancer</arm_group_label>
    <arm_group_label>Premalignant lesions</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Salivary sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: patients with malignant lesions will be diagnosed through clinical and&#xD;
        histopathological examination of tissue biopsy.&#xD;
&#xD;
        Group 2: patients with oral potentially malignant lesions will be diagnosed clinically and&#xD;
        histopathological examination of tissue biopsy.&#xD;
&#xD;
        Group 3: healthy individuals who will be examined clinically through conventional visual&#xD;
        and tactile examination to ensure no oral lesions are present and through thorough medical&#xD;
        history&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1: patients with malignant lesions will be diagnosed through clinical and&#xD;
        histopathological examination of tissue biopsy.&#xD;
&#xD;
        Group 2: patients with oral potentially malignant lesions will be diagnosed clinically and&#xD;
        histopathological examination of tissue biopsy.&#xD;
&#xD;
        Group 3: healthy individuals who will be examined clinically through conventional visual&#xD;
        and tactile examination to ensure no oral lesions are present and through thorough medical&#xD;
        history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fat'heya Zahran</last_name>
    <phone>01060775113</phone>
    <email>fatheya.zahran@dentistry.cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noha Azab</last_name>
    <phone>01001381954</phone>
    <email>noha.adel@dentistry.cu.edu.eg</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Salma mohamed saad-eldin mahmoud</investigator_full_name>
    <investigator_title>Resident at the faculty of Dentistry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Leukoplakia, Oral</mesh_term>
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

